Seelos Therapeutics, INC 8-K filings

Seelos Therapeutics has filed for Chapter 11 bankruptcy, leading to its stock being moved to the OTC Pink Market and the suspension of its SEC reporting obligations.

Seelos Therapeutics has announced a second postponement of its 2024 Annual Meeting of Stockholders due to an anticipated lack of quorum.

Seelos Therapeutics will be delisted from the Nasdaq due to non-compliance with minimum stockholders' equity requirements and will begin trading on the OTCQB market.

Seelos Therapeutics has been granted a final extension by the Nasdaq Hearings Panel to regain compliance with listing requirements, specifically regarding minimum share price and market value.

Seelos Therapeutics has postponed its 2024 Annual Meeting of Stockholders due to an anticipated lack of quorum, rescheduling it for October 25, 2024.

Seelos Therapeutics has implemented a 1-for-16 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Seelos Therapeutics has signed a Material Transfer Agreement with the U.S. Army to evaluate its drug, SLS-002, for the treatment of PTSD in a clinical trial.

Seelos Therapeutics has entered into an agreement with Lind Global Asset Management to convert a $22 million convertible note into common stock upon a fundamental transaction, aiming to meet Nasdaq's continued listing standards.

Seelos Therapeutics has announced the date for its 2024 annual shareholder meeting and established deadlines for shareholder proposals and director nominations.

Seelos Therapeutics has received an extension from Nasdaq to regain compliance with listing requirements, specifically regarding minimum share price and market value.

Seelos Therapeutics has amended its convertible promissory note with Lind Global Asset Management, providing relief from minimum cash balance requirements until October 31, 2024, and extending the deadline for stockholder approval related to the note.

Seelos Therapeutics has entered into an agreement with warrant holders to exercise existing warrants for cash, resulting in gross proceeds of approximately $573,240 and the issuance of new warrants.

Seelos Therapeutics has amended its convertible promissory note with Lind Global Asset Management, providing temporary relief from minimum cash balance requirements and reducing the share price for repayments.

Seelos Therapeutics, Inc. has entered into a securities purchase agreement to raise approximately $1.1 million through a registered direct offering and concurrent private placement.

Seelos Therapeutics has enacted a 1-for-8 reverse stock split and reduced its authorized shares to regain compliance with Nasdaq's minimum bid price requirement.

Seelos Therapeutics has announced a 1-for-8 reverse stock split effective May 16, 2024, to regain compliance with Nasdaq's minimum bid price requirement.

Seelos Therapeutics has announced a workforce reduction, received a delisting notice from Nasdaq, and amended its convertible promissory note with Lind Global Asset Management.

Seelos Therapeutics has amended its convertible promissory note with Lind Global Asset Management, increasing the principal amount by $1.49 million and modifying certain terms.

Seelos Therapeutics reported top-line results from its Phase 2/3 ALS study, showing a potential signal of efficacy in a pre-specified subgroup despite not meeting statistical significance in the primary endpoint.

Seelos Therapeutics has successfully raised approximately $4 million through a registered direct offering and concurrent private placement to fund general corporate activities and advance its product pipeline.

Seelos Therapeutics has secured FDA agreement on modified endpoints for its Phase III trial of SLS-002 for major depressive disorder, paving the way for further development.